SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (486)4/10/2003 11:59:39 AM
From: scaram(o)uche  Read Replies (1) of 897
 
>> about the DSMB for Tarceva trial recommending against continuation of therapy because of a "safety signal" <<

The DSMB recommended that Tarceva be discontinued, in a NSCLC trial, upon tumor progression or at the time where second line chemotherapy is initiated. The panel did not point to any safety or efficacy data such that the trial should be halted. Patients whose cancers have not progressed on therapy will continue to be treated.

Nonetheless, the "safety signal" isn't a positive.

As for other EGFR antagonists, one might expect objective responses in a fraction of patients, and little if any effect in most patients. We'll see, as the trial continues through this wrinkle.

Disclosure: not a Goddard fan.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News